INTRODUCTION

Nonsteroidal anti-inflammatory drugs (NSAIDs) offer analgesic efficacy similar to that of morphine and meperidine\(^1,2\) and have been used as part of multimodal postoperative analgesic regimens to reduce the necessity of opioids and their associated side effects, and hospital length of stay.\(^3\text{-}^{11}\) The incorporation of NSAIDs in the postoperative period has shown to reduce opioid consumption by 30\%-50\%\(^1,2\) with an associated decrease in postoperative nausea, vomiting, and sedation.\(^13\) Ketorolac tromethamine (ketorolac) is an NSAID that can be administered parenterally and is not associated with central nervous system or cardiorespiratory depression or postoperative nausea and vomiting.\(^1,14\)

NSAIDs and ketorolac, due to their nonselective inhibition of Cyclooxygenase (COX)-1 and COX-2 enzymes on platelets, gastrointestinal mucosa, and kidneys, have been associated with a variety of adverse events.\(^15\) Most pertinent to surgery, inhibition of COX by NSAIDs has shown to alter platelet function and prolong bleeding times in healthy volunteers\(^2,15\text{-}^{17}\) even though bleeding times generally remain within normal limits.\(^16\) Due to this impact on the coagulation cascade and potential to result in hemorrhagic complications, there is a hesitation to utilize ketorolac postoperatively.

BACKGROUND: Nonsteroidal anti-inflammatory drugs have been used as part of multimodal postoperative analgesic regimens to reduce the necessity of opioids. However, due to its effect on platelet function, there is a hesitation to utilize ketorolac postoperatively. The goal of this study is to analyze our experience utilizing ketorolac in patients who underwent major cranial vault remodeling (CVR) for craniosynostosis with an emphasis on postoperative hemorrhage and complications.

METHODS: A retrospective review was performed for all patients undergoing CVR for craniosynostosis from 2013 to 2017. Primary outcomes were hemorrhagic complications. Secondary outcomes included length of stay, emesis, and doses of pain medication.

RESULTS: Seventy-four consecutive patients met inclusion criteria. Forty-three (58.1\%) received ketorolac. Seven in the ketorolac group (16\%) and 9 in the control group (29\%) received intraoperative blood transfusion (\(P = 0.25\)). One in the ketorolac group (2.3\%) and 2 in the control group (3.1\%) necessitated postoperative transfusion (\(P = 0.56\)). Patients who received ketorolac required less morphine doses (2.1 versus 3.3 doses; \(P = 0.02\)) and had a reduced length of stay (2.1 versus 2.6 nights; \(P = 0.04\)).

CONCLUSIONS: This is the first study to demonstrate that postoperative ketorolac is not associated with an increase in hemorrhagic complications or transfusion risk in children who underwent CVR for craniosynostosis. Patients administered ketorolac required less morphine and had a hospital length of stay. We hope this study stimulates more well-done prospective trials analyzing the role that ketorolac can play in an effective and safe postoperative analgesia regimen. (Plast Reconstr Surg Glob Open 2019;7:e2401; doi: 10.1097/GOX.0000000000002401; Published online 19 August 2019.)
olac postoperatively and there are conflicting results over its use and increased risk of bleeding in the literature.\textsuperscript{11–22}

The rate of allogenic blood transfusion in cranial vault remodeling (CVR) for craniosynostosis has been reported to be as high as 80%–100%.\textsuperscript{23–27} Many surgeons have been reluctant to use ketorolac after major cranial procedures to avoid postoperative bleeding and the necessity for additional transfusions. However, a recent study by Richardson et al\textsuperscript{28} showed that routine ketorolac administration was not associated with hemorrhage in children undergoing a wide range of neurosurgical procedures. At our institution, the rate of intraoperative hemorrhage requiring transfusion is 21%, and postoperative transfusions are only required by 4% of patients. As a result, we have incorporated ketorolac into our postoperative pathway for children undergoing CVR. The goal of this study is to analyze our experience utilizing ketorolac in patients who underwent major CVR for craniosynostosis at our institution with an emphasis on postoperative hemorrhage and complications.

**PATIENTS AND METHODS**

Following approval from our Institutional Review Board, a retrospective review was performed for all patients undergoing CVR for craniosynostosis from December 2013 to September 2017. Patients undergoing limited craniectomies (strip or Pi procedures) were excluded. All patients were placed on a perioperative blood management protocol that was instituted in December 2013. No routine postoperative drains or head wrap was utilized, and no postoperative imaging was performed. Routine neurologic examinations were performed during the hospitalization to monitor for the signs of intracranial bleeding.

Nonsteroidal anti-inflammatory medications, ibuprofen or ibuprofen/ketorolac, were written for all patients postoperatively. Ibuprofen was ordered at 10 mg/kg per dose and intravenous ketorolac at 0.25 mg/kg at a frequency of every 6 hours as needed. When both were ordered, the decision to administer ibuprofen or ketorolac was made by the bedside nurse, typically based on the patient’s ability to take medications orally. The surgical team did not influence the use or administration of ketorolac. Patients who received ibuprofen only served as the control group for this study.

Demographic data (age at the time of surgery and sex), type of synostosis based on involved sutures (simple versus complex), type of CVR (anterior CVR [ACVR] or posterior CVR [PCVR]), primary or secondary surgery, procedural time, crystallloid and colloid use during the surgery (ml/kg), recycled autologous red cell volume (ml/kg), estimated blood loss (ml), the rate of intraoperative transfusion, the rate of postoperative transfusion, and follow-up time (in days) were collected. Postoperative hemoglobin trend was evaluated by comparing hemoglobin values drawn at 3 scheduled time points (occasionally more) after the procedure. The percent change in hemoglobin was calculated ([discharge hemoglobin – the first postoperative hemoglobin]/the first postoperative hemoglobin × 100). For the 3 patients who received postoperative blood transfusions, the discharge hemoglobin was substituted by pretransfusion hemoglobin to better reflect the decrease in hemoglobin. Confounding variables, such as comorbidities with increased bleeding risk (eg, factor deficiencies, von Willebrand disease) or home medications with potential anticoagulation properties (eg, aspirin, valproic acid), were also analyzed.

Primary outcomes were postoperative hemorrhagic complications such as postoperative transfusion rate, change in hemoglobin over the postoperative period, and hematoma and intracranial hemorrhage rates. Hematomas were defined as a sanguineous fluid collection that required intervention in the postoperative period. Secondary outcomes included the development of renal insufficiency/failure and gastrointestinal bleeding, which are measures related to the safety profile of ketorolac. Renal insufficiency/failure was defined as decreased urine output or increased serum creatinine in the postoperative period. Gastrointestinal bleeding was defined as the presence of hematemesis or melena. Other variables were length of hospitalization (measured as number of nights spent in the hospital after the procedure), episodes of emesis, and doses of morphine, oxycodone, ketorolac, and ibuprofen administered during the hospitalization.

Categorical variables are presented as prevalence and percentages. Continuous variables are presented as means ± SD, range. Categorical variables were examined using the chi-square or Fisher’s exact test as appropriate. Continuous variables were examined using a Student’s t test. Statistical significance was set at \( P < 0.05 \). GraphPad Prism 7.0 (GraphPad Software, La Jolla, Calif.) was used for all analyses.

**RESULTS**

**Demographics and Clinical Characteristics**

Seventy-four consecutive patients who underwent CVR for craniosynostosis were identified during the study period. The median age of patients was 0.9 years (range, 0.6–16.1 years). Thirty patients (40.5%) were female and 44 (59.4%) were males. The types of synostoses included 24 (32%) sagittal, 15 (20%) metopic, 10 (13%) unilateral coronal, 3 (4%) lambdoid, and 22 (30%) multisuture or complex synostosis patients. Forty-three patients (58%) underwent ACVR, and 31 patients (42%) underwent PCVR. Thirteen patients (17%) underwent CVR as a secondary CVR procedure. The mean procedural time was 319±76 minutes (range, 201–580 minutes). No patients had comorbidities that would increase bleeding risk or were on any blood thinning medication at the time of the procedure (Table 1).

Of the 74 consecutive patients included in the study, 43 (58.1%) patients received at least 1 dose of ketorolac and the remaining 31 (41.9%) patients did not receive any ketorolac, making up the control group. There was no significant difference between the groups in regard to age (2.0 versus 3.1; \( P = 0.21 \)), type of synostosis (complex versus simple: 13/30 versus 8/23; \( P = 0.6 \)), or sex (male/female: 30/13 versus 14/17; \( P = 0.05 \)) (Table 2).
Perioperative Findings

The only significant difference between the ketorolac and control groups was a higher ratio of ACVR to PCVR in the control group ($24/7$ versus $19/24; P < 0.01$). Operative time, intraoperative crystalloid use, autologous red cell recycling volume, and estimated blood loss were not different between the groups. When calculated per body weight, the amount of colloid administered intraoperatively was higher in the ketorolac group ($9.5 ± 2.7$ versus $5.1 ± 6$ ml/kg; $P = 0.01$). Seven patients in the ketorolac group (16%) and 9 patients in the control group (29%) received intraoperative transfusion ($P = 0.25$). One patient in the ketorolac group (2.3%) and 2 patients in the control group (3.1%) necessitated postoperative transfusion ($P = 0.56$). For the ketorolac group, the mean first postoperative hemoglobin was lower than the control group at 9.2 versus 9.7 g/dl, respectively, but this difference was not statistically significant ($P = 0.21$). Although the discharge hemoglobin was lower in the ketorolac group (8.2 versus 9.1 g/dl; $P = 0.02$), the postoperative change in hemoglobin was similar between the 2 groups (10% versus 6.7% decrease in hemoglobin; $P = 0.1$) (Table 3).

Postoperative Outcomes

The average time between the end of the procedure and ketorolac administration was 4 hours ± 19 minutes (range, 40 minutes to 24 hours). The mean number of ketorolac doses given during hospitalization was $3.2 ± 1.8$ (range, 1–11). Patients in the ketorolac group required less morphine than the control group (2.1 versus 3.3 doses; $P = 0.02$), whereas oxycodone doses were similar between the 2 groups ($P = 0.21$). In the ketorolac group, less doses of ibuprofen were administered as it was substituted by ketorolac ($3.8$ versus $6.1; P < 0.01$). Emesis rates were similar between the 2 groups. The hospital length of stay was shorter in the ketorolac group (2.1 nights) than in the control group (2.6 days) ($P < 0.05$). No patients experienced postoperative hematoma, oliguria or increase in creatinine levels that would indicate renal insufficiency/failure or hematemesis, melena, or other suggestion of gastrointestinal hemorrhage (Table 4).

DISCUSSION

Effective postsurgical analgesia is a critical aspect of the patient recovery because it can contribute to faster patient mobilization, shorter hospital stays, and reduced health care costs. NSAIDs can be an effective component of the multimodal postoperative pathway and can result in improved postoperative analgesia with decreased opioid utilization. This is associated with a more rapid return of gastrointestinal function, shortened hospital length of stay, and reduced health care costs.

---

Table 1. Demographics of Patient Cohort

| Demographic                                      | N (%)          |
|--------------------------------------------------|----------------|
| Total no. patients                               | 74             |
| Age at surgery, median (range in years)          | 0.9 (0.6–16.1) |
| Sex, n (%)                                       |                |
| Female                                           | 30 (40.5)      |
| Male                                             | 44 (59.4)      |
| Synostoses, n (%)                                |                |
| Sagittal                                         | 24 (32)        |
| Metopic                                          | 15 (20)        |
| Unilateral coronal                               | 10 (13)        |
| Sagittal                                         | 24 (32)        |
| Lambdoid                                         | 3 (4)          |
| Multisuture or complex                           | 22 (30)        |
| Remodeling, n (%)                                |                |
| Anterior cranial vault                           | 43 (58)        |
| Posterior cranial vault                          | 31 (42)        |
| Procedure time, mean (range in minutes)          | 319 (201–580)  |

Table 2. Demographic and Clinical Characteristics of Ketorolac and Control Patients

|                      | Ketorolac (n = 43) | Control (n = 31) | P     |
|----------------------|--------------------|------------------|-------|
| Mean age at surgery in years | 2.0 ± 1.9          | 3.1 ± 4.6        | 0.21  |
| Male-to-female ratio  | 30/13              | 14/17            | 0.05  |
| Type of synostosis   |                    |                  |       |
| (simple/complex)      | 30/13              | 23/8             | 0.6   |

Table 3. Transfusion Rates and Hemoglobin Changes

|                      | Ketorolac (n = 43) | Control (n = 31) | P     |
|----------------------|--------------------|------------------|-------|
| ACVR/PCVR ratio      | 19/24              | 24/7             | <0.01*|
| Operative time (min) | 320                | 319              | 0.96  |
| Crystalloid use (ml/kg) | 95±27              | 87±27            | 0.19  |
| Colloid use (ml/kg)  | 9.5±7.8            | 5.1±6.0          | 0.01* |
| Recycled autologous cell volume (ml/kg) | 8.8±6.7            | 6.7±4.2          | 0.13  |
| Estimated blood loss (ml) | 308                | 304              | 0.95  |
| Intraoperative transfusion rate | 16% (7/43)         | 29% (9/31)       | 0.25  |
| Postoperative transfusion rate | 1/43 (2%)          | 2/31 (6%)        | 0.56  |
| Mean first postoperative Hgb value (g/dl) | 9.2                | 9.7              | 0.21  |
| Mean discharge Hgb value (g/dl) | 8.2                | 9.1              | 0.02* |
| Decrease in Hgb      | 10%                | 6.7%             | 0.1   |

*P < 0.05.

Hgb, hemoglobin.
A similar study by Richardson et al. found that routine morphine doses had decreased hospital length of stay. Specific to patients undergoing craniosynostosis correction, numerous clinical trials have demonstrated that the NSAID ketorolac is as effective as morphine and even more effective than codeine in the pediatric population. To patients undergoing craniotomies, scheduled doses of NSAIDs have shown to improve analgesia and decrease opioid requirement. Additionally, the use of nonnarcotic analgesics is particularly advantageous after cranial procedures to monitor the central nervous system with postoperative serial neurologic examinations. In our study, we also corroborated prior studies that patients receiving ketorolac required less morphine in the postoperative period. By utilizing nonopioid analgesics, there may be early return to daily activities. Although we cannot argue causality, there seems to be an association among ketorolac use, decreased opioid requirement, and shorter hospital length of stay.

However, concerns over the potential of NSAIDs, including toradol and ibuprofen, to cause postoperative hemorrhage have prevented widespread utilization. The risk of bleeding is of greater importance in procedures where postoperative hemorrhage may lead to catastrophic complications. For this reason, some neurosurgeons are reluctant to use ketorolac and other NSAIDs in the acute postoperative period. Although early studies raised concerns for an increased risk of bleeding with the use of NSAIDs and ketorolac in pediatric and adult populations, this was not corroborated in further studies. A meta-analysis published in 2014 which analyzed 27 studies with 2,314 patients who underwent a variety of surgical procedures found that postoperative bleeding was not increased with ketorolac administration and that ketorolac resulted in superior pain control. Additionally, a case-control study was able to demonstrate no increased risk in the occurrence of symptomatic postoperative intracranial hemorrhage with the administration of ketorolac after elective intracranial procedures in adults.

In our study, we were able to demonstrate in a pediatric patient population undergoing major CVR for craniosynostosis that the administration of ketorolac as part of the postoperative analgesia regimen did not result in hemorrhagic complications or need for transfusion. Despite there being a significant difference in postoperative hemoglobin between the ketorolac and control groups, the percent decrease in hemoglobin was not significant and it typically did not result in physical manifestations warranting transfusion. Additionally, others have proposed that the threshold for transfusion in the pediatric population after CVR should be 7.5–8.0 g/dl and the mean discharge hemoglobin was 8.2 g/dl in the ketorolac group. Patients who received ketorolac also required less morphine doses and had decreased hospital length of stay. A similar study by Richardson et al. found that routine perioperative ketorolac administration was not associated with a significant increase in the risk of bleeding in pediatric neurosurgery patients. This study analyzed patient outcomes by type of surgical procedure and found that hemorrhage on examination or demonstrated through imaging was associated with craniosynostosis repair or Chiari malformation decompression as compared to intradural placement of a catheter or endoscope. This might be explained by the amount of dissection required for a craniectomy in CVR and the potential for increased blood loss and accumulation of blood and serous fluids in the surgical site. However, our study was specific to CVR and we did not demonstrate an increased risk of hemorrhagic complications or need for transfusion. Additionally, as patients had a major cranial procedure, it was expected that all would have a serosanguinous fluid collection in the first week postoperatively. However, all fluid collections resolved without any intervention and no patients in our series required drainage or intervention. Thus, we can make the conclusion that ketorolac was not associated with an increased rate of clinically significant hematoma.

The optimal timing of ketorolac delivery is an area of research and contention. Some have proposed that administration before incision or before primary hysteresis might be responsible for the observed increased bleeding in some of the studies. In our cohort, we did not administer ketorolac before or during the surgery and the median time between the end of surgery and the time of ketorolac administration was about 3 hours. Of note, we used ketorolac at the lowest pharmacologic dose (0.25 mg/kg/dose, up to 15 mg/dose), whereas others have used 0.5–1 mg/kg in children and 30–50 mg/d in adults. Importantly in our patient population, our application of a formalized, well-established, and effective blood management protocol and strategic hemostasis allowed us to have a 4% postoperative transfusion rate over the study period. This can be compared with postoperative transfusion rates in the literature as high as 34%–42%. Our low transfusion rate represents a single-center experience, and, thus, our results may not be transferrable to all centers.

Our study is not without limitations. This study is a retrospective and nonrandomized cohort study. In a series of consecutive patients, results will typically improve over time and our strategies for blood management and hemostasis continue to evolve. Thus, although there is some degree of experience bias, importantly, the ketorolac group was not isolated to the most recent patients. Also, the ketorolac group had a higher proportion of ACVR. These are typically associated with higher rates of blood loss and transfusion, so the difference although significant further supports the safety of ketorolac. Although concerns have been raised that selective/nonselective COX inhibitor use may adversely affect osteogenic activity, our goal was not to evaluate cranial defects. Although we do not believe that there is an increase in cranial defect rate with ketorolac utilization, we will continue to follow our patients to critically analyze our outcomes.
CONCLUSIONS

In conclusion, this is the first study to demonstrate that postoperative ketorolac is not associated with increased bleeding or transfusion risk in children who underwent CVR for craniosynostosis. Additionally, patients administered ketorolac required less morphine for pain control and had a shorter hospital length of stay. We hope that this study stimulates more well-done prospective trials analyzing the role that ketorolac can play in an effective and safe postoperative analgesia regimen.

REFERENCES

1. Bean-Lijewski JD, Hunt RD. Effect of ketorolac on bleeding time and postoperative pain in children: a double-blind, placebo-controlled comparison with meperidine. J Clin Anesth. 1996;8:25–30.
2. Gillis JC, Brogden RN. Ketalorac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188.
3. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Anesth Analg. 2002;83:630–641.
4. Arsalani-Zaedeh R, ElFaxd D, Yassin N, et al. Evidence-based review of enhancing postoperative recovery after breast surgery. Br J Surg. 2011;98:181–196.
5. Kehlet H. Multimodal approach to control postoperative pathology and rehabilitation. Br J Anaesth. 1997;78:606–617.
6. Hval K, Kjetil H, Thagaard KS, et al. The prolonged postoperative analgesic effect when dexamethasone is added to a nonsteroidal antiinflammatory drug (rofecoxib) before breast surgery. Anesth Analg. 2007;105:481–486.
7. Elvir-Lazo OL, White PF. The role of multimodal analgesia in pain management after ambulatory surgery. Curr Opin Anaesthesiol. 2010;23:697–703.
8. Fassoulaki A, Triga A, Melemeni A, et al. Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesth Analg. 2005;101:1427–1432.
9. Bharti N, Bala I, Narayan V, et al. Effect of gabapentin pre-treatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. Acta Anaesthesiol Taiwan. 2013;51:10–13.
10. Pettersson N, Perbeck L, Hahn RG. Efficacy of subcutaneous and topical local anaesthesia for pain relief after resection of malignant breast tumours. Eur J Surg. 2001;167:825–830.
11. De Oliveira GS Jr, Agarwal D, Benzon HT. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg. 2012;114:424–433.
12. Marret E, Kurdi O, Zufferey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–1260.
13. Fletcher D, Benoist JM, Gautron M, et al. Isobolographic analysis of interactions between intravenous morphine, propacetamol, and diclofenac in carrageenin-injected rats. Anesth Analg. 1997;87:317–326.
14. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77:162–184.
15. Bauer KA, Gerson W, Wright C 4th, et al. Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. J Clin Anesth. 2010;22:510–518.
16. Forrest JB, Heitlinger EL, Revell S. Ketalorac for postoperative pain management in children. Drug Saf. 1997;16:309–329.
17. Niemi TT, Backman JT, Syrjälä MT, et al. Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol Scand. 2000;44:69–74.
18. Bailey R, Sinha C, Burgess LP. Ketalorac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, double-blind study. Laryngoscope. 1997;107:166–169.
19. Russy LM, Houck CS, Sullivan LJ, et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg. 1995;80:226–229.
20. Agrawal A, Gerson CR, Seligman I, et al. Postoperative hemorrhage after tonsillectomy: use of ketorolac tromethamine. Otolaryngol Head Neck Surg. 1999;120:335–339.
21. Richardson MD, Palmeri NO, Williams SA, et al. Routine perioperative ketorolac administration is not associated with hemorrhage in pediatric neurosurgery patients. J Neurosurg Pediatr. 2016;17:107–115.
22. Howard ML, Warhurst RD, Sheehan C. Safety of continuous infusion ketorolac in postoperative coronary artery bypass graft surgery patients. Pharmacy (Basel). 2016;4:E22.
23. Naighbian H, Song M, Jayomohan J, et al. Long-term results in isolated metopic synostosis: the Oxford experience over 22 years. Plast Reconstr Surg. 2018;142:506e–515e.
24. Birgfeld CB, Dufton L, Naumann H, et al. Safety of open cranial vault surgery for single-suture craniosynosysostosis: a case for the multidisciplinary team. J Craniomaxillofac Surg. 2015;26:2052–2058.
25. Oppenheimer AJ, Ranganathan K, Levi B, et al. Minimizing transfusions in primary cranial vault remodeling: the role of amnioncacoic acid. J Craniomaxillofac Surg. 2014;25:82–86.
26. Nguyen TT, Lam HV, Phillips M, et al. Intraoperative optimization to decrease postoperative PRBC transfusion in children undergoing craniofacial reconstruction. Paediactr Anaesth. 2015;25:294–300.
27. Kucuk A, Tumturk A, Gergin IS, et al. The management of blood loss in non-syndromic craniosynosysostosis patients undergoing barrel stave osteotomy. Turk Neurosurg. 2017;27:138–141.
28. Ramsing J, Ostergaard D, Walther-Larsen S, et al. Analgesic eficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand. 1998;42:770–775.
29. Gunter JB, Varughese AM, Harrington JF, et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg. 1995;81:1136–1141.
30. Fearon JA, Dimas V, Dithakasem K, et al. A randomized controlled trial of oral versus intravenous administration of a nonnarcotic analgesia protocol following pediatric craniomaxinosysostosis corrections on nausea and vomiting rates. J Craniofac Surg. 2015;26:1951–1953.
31. Pundazy JP, Reichert CC, Merrick PM. Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Can J Anaesth. 1996;43:221–225.
32. Dolmatova EV, Imaev AA, Lubnin AY. ‘Scheduled’ dosing of lornoxicam provides analgesia superior to that provided by ‘on request’ dosing following craniotomy. Eur J Anaesthesiol. 2009;26:633–637.

Niyant Patel, MD
Akron Children’s Hospital Specialty Care
Considine Professional Building
215 W. Bowery St.
Suite 3300
Akron, Ohio 44308
E-mail: npatel2@akronchildrens.org
33. Smyth MD, Banks JT, Tubbs RS, et al. Efficacy of scheduled non-narcotic analgesic medications in children after suboccipital craniectomy. J Neurosurg. 2004;100(2 Suppl Pediatrics):183–186.
34. Magni G, La Rosa I, Melillo G, et al. Intracranial hemorrhage requiring surgery in neurosurgical patients given ketorolac: a case-control study within a cohort (2001-2010). Anesth Analg. 2013;116:443–447.
35. Splinter WM, Rhine EJ, Roberts DW, et al. Preoperative ketorolac increases bleeding after tonsillectomy in children. Can J Anaesth. 1996;43:560–563.
36. Gobble RM, Hoang HL, Kachniarz B, et al. Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2014;133:741–755.
37. Stricker PA, Fiadjoe JE, Kilbaugh TJ, et al. Effect of transfusion guidelines on postoperative transfusion in children undergoing craniofacial reconstruction surgery. Pediatr Crit Care Med. 2012;13:e357–e362.
38. Stricker PA, Shaw TL, Desouza DG, et al. Blood loss, replacement, and associated morbidity in infants and children undergoing craniofacial surgery. Paediatr Anaesth. 2010;20:150–159.
39. White PF, Raeder J, Kehlet H. Ketorolac: its role as part of a multimodal analgesic regimen. Anesth Analg. 2012;114:250–254.
40. Pradhan BB, Tatsumi RL, Gallina J, et al. Ketorolac and spinal fusion: does the perioperative use of ketorolac really inhibit spinal fusion? Spine (Phila Pa 1976). 2008;33:2079–2082.
41. Eberson CP, Pacicca DM, Ehrlich MG. The role of ketorolac in decreasing length of stay and narcotic complications in the postoperative pediatric orthopaedic patient. J Pediatr Orthop. 1999;19:688–692.